Hematologic Malignancy
Lymphoid Neoplasm
CI-CAN-00009335Explore in graph →
Hematologic2,419 active trials60 approved drugs271 evidence items
- OncoTree
- LNM
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00009335Explore in graph →
Clinical trials
8,886 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,374)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07200102 | Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma | recruiting | Phase 1 | 20 | Washington University School of MedicineOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT07234162 | A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19) | recruiting | Phase 3 | 218 | Dizal PharmaceuticalsINDUSTRY | 3 | Jun 8, 2026 | clinicaltrials |
| NCT03858205 |
| Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma |
| recruiting |
| N/A |
| 100 |
| University of Southern CaliforniaOTHER |
| 1 |
| Jun 5, 2026 |
| clinicaltrials |
| NCT05405387 | Impact of Budesonide on Incidence of ≥ Gr2 Diarrhea in Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplant(IMPACT) | recruiting | Phase 2 | 120 | University of UtahOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT07278856 | Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas | recruiting | Phase 1 | 20 | City of Hope Medical CenterOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT05243797 | Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation(MajesTEC-4) | recruiting | Phase 3 | 1,594 | European Myeloma Network B.V.NETWORK | 25 | Jun 4, 2026 | clinicaltrials |
| NCT05800210 | Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases | recruiting | Phase 2 | 20 | University of FloridaOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT06131801 | Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution | recruiting | — | 30 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT06271057 | Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse | recruiting | Phase 2 | 65 | The Lymphoma Academic Research OrganisationOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT06948786 | Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial | recruiting | Phase 2 | 22 | University of WashingtonOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT06974786 | Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma(FASTER) | recruiting | Phase 2 | 100 | SCRI Development Innovations, LLCOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07168980 | Chemotherapy With Rituximab for Aggressive B-NHL in Children and Adolescents(B-NHL) | recruiting | Phase 2 / Phase 3 | 87 | Children's Cancer Group, ChinaNETWORK | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07255898 | A Study of BL-M24D1 in Patients With Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies | recruiting | Phase 1 | 33 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07490613 | A Phase I Study of SHR-3836 in Patients With Multiple Myeloma | recruiting | Phase 1 | 99 | Shanghai Hengrui Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07528352 | External Beam Radiotherapy Followed by Bispecific Antibody Therapy for Relapsed/Refractory DLBCL(REBEL) | recruiting | Phase 1 | 12 | University of UtahOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07581704 | Sirolimus Pre-conditioning on T Cell Activity and T-cell Engaging Bispecific Antibody Efficacy in Multiple Myeloma | recruiting | Phase 1 | 10 | Christopher StrouseOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07626476 | Autologous BCMA-targeted CAR-T Cell Injection for Relapsed/Refractory Light Chain Amyloidosis | recruiting | Early Phase 1 | 30 | Beijing Boren HospitalOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07623850 | A Phase I Study of JLM019 Injection(JLM019) | recruiting | Phase 1 | 115 | Jecho Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Jun 3, 2026 | clinicaltrials |
| NCT05145400 | Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma | recruiting | Phase 2 | 50 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT07350850 | A Multicenter, Prospective Clinical Trial With a Concurrent Control Evaluating Methotrexate Combined With Rituximab,Sintilimab and Pirtobrutinib vs. Investigator-Selected Standard of Care in Treatment-Naive PCNSL(PRIME-PCNSL) | recruiting | Phase 2 | 77 | Tongji HospitalOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT07555431 | Dolutegravir Versus Dolutegravir in Combination With Tenofovir for the Treatment of HTLV-1 Infection(DOT-H) | recruiting | Phase 2 | 146 | Carlos BritesOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT04139304 | A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma | recruiting | Early Phase 1 | 15 | AIDS Malignancy ConsortiumNETWORK | 1 | Jun 1, 2026 | clinicaltrials |
| NCT04776395 | Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma | recruiting | Phase 2 | 68 | Emory UniversityOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT05663502 | Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers | recruiting | — | 200 | AIDS Malignancy ConsortiumNETWORK | 1 | Jun 1, 2026 | clinicaltrials |
| NCT07226934 | An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers | recruiting | N/A | 40 | Washington University School of MedicineOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT04195633 | Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies | recruiting | Phase 2 | 60 | Fred Hutchinson Cancer CenterOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT04211259 | Loratadine for the Reduction of G-CSF Induced Bone Pain in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization | recruiting | Early Phase 1 | 70 | Rutgers, The State University of New JerseyOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT04460235 | Clinical Trial Assessing the Immunogenicity of an Anti-pneumococcal Vaccination Strategy (PCV13+PPV23 Versus PREVENAR20) in Adult Patients Treated for a Lymphoma(HEMATOVAC) | recruiting | Phase 4 | 160 | Poitiers University HospitalOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT04508790 | Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma | recruiting | Phase 2 | 29 | City of Hope Medical CenterOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT05418088 | Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies | recruiting | Phase 1 | 54 | Sumithira VasuOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT06822855 | Changing Paragidms In The Prognostic Assessment Of Hodgkin Lymphoma(LH_BIO) | recruiting | — | 755 | Azienda USL Reggio Emilia - IRCCSOTHER_GOV | 1 | May 29, 2026 | clinicaltrials |
| NCT05100056 | A Study of Brentuximab Vedotin in Adults With Hodgkin's Lymphoma(BV-MAZOVIA) | recruiting | — | 70 | TakedaINDUSTRY | 1 | May 27, 2026 | clinicaltrials |
| NCT06458439 | Epcoritamab-CAR T Cells for Large B-cell Lymphomas | recruiting | Phase 2 | 31 | Abramson Cancer Center at Penn MedicineOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT07541391 | Autologous Chimeric Antigen Receptor (CAR) T-cells Targeting the Kappa Myeloma Antigen (KMA) in Kappa Restricted Multiple Myeloma Patients With Relapsed/Refractory Disease(KOALA) | recruiting | Phase 1 | 12 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT07608978 | Efficacy and Safety of Polatuzumab Vedotin in Combination With Zanubrutinib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma of the MCD/BN2/N1 Subtypes(Pola-ZRCHP) | recruiting | Phase 2 | 35 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT07609030 | A Cognitive Training Intervention for Improving Cognitive and Neurological Outcomes in Patients Undergoing Treatment for Relapsed or Refractory Multiple Myeloma or B-cell Non-Hodgkin Lymphoma | recruiting | N/A | 90 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT07609576 | Infectious Complications in Hematological Patients Under Treatment With Bispecific Antibodies. | recruiting | — | 350 | Infanta Leonor University HospitalOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT05480449 | Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy) | recruiting | Phase 1 / Phase 2 | 115 | Stephan Grupp MD PhDOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT07001384 | A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL) | recruiting | Phase 1 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT07052916 | A Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties | recruiting | N/A | 60 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT05616325 | Long-term Ovarian Fertility in Patients Treated for Lymphoma.(FERTILymph) | recruiting | — | 270 | University Hospital, LilleOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT05783609 | Epcoritamab and Rituximab for First-line Follicular Lymphoma | recruiting | Phase 2 | 100 | Reid Merryman, MDOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT06812858 | PD-1 Inhibitors Maintenance for cHL Post-autoHCT | recruiting | Phase 2 | 83 | St. Petersburg State Pavlov Medical UniversityOTHER | 2 | May 22, 2026 | clinicaltrials |
| NCT07138209 | A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma | recruiting | Phase 3 | 228 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 22, 2026 | clinicaltrials |
| NCT02877303 | Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia | recruiting | Phase 2 | 80 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT05011045 | Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies | recruiting | — | 100 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT05978141 | A Registry for People With T-cell Lymphoma | recruiting | — | 1,000 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT06098430 | Patient-Reported Outcomes and Quality of Life in Adult and Pediatric Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL) | recruiting | — | 100 | St. Jude Children's Research HospitalOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT07013565 | Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL(ACCELERATE) | recruiting | Phase 2 | 20 | New York Medical CollegeOTHER | 1 | May 20, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jun 8, 2026source: clinicaltrials